DK1117435T3 - Muteret cholera-holotoxin som adjuvans - Google Patents
Muteret cholera-holotoxin som adjuvansInfo
- Publication number
- DK1117435T3 DK1117435T3 DK99951639T DK99951639T DK1117435T3 DK 1117435 T3 DK1117435 T3 DK 1117435T3 DK 99951639 T DK99951639 T DK 99951639T DK 99951639 T DK99951639 T DK 99951639T DK 1117435 T3 DK1117435 T3 DK 1117435T3
- Authority
- DK
- Denmark
- Prior art keywords
- adjuvant
- amino acid
- holotoxin
- cholera holotoxin
- mutant cholera
- Prior art date
Links
- 206010008631 Cholera Diseases 0.000 title abstract 4
- 239000002671 adjuvant Substances 0.000 title abstract 3
- 235000001014 amino acid Nutrition 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 4
- 229930186900 holotoxin Natural products 0.000 abstract 3
- 230000000890 antigenic effect Effects 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 241000233866 Fungi Species 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 235000003704 aspartic acid Nutrition 0.000 abstract 1
- 244000052616 bacterial pathogen Species 0.000 abstract 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Biological Depolymerization Polymers (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10243098P | 1998-09-30 | 1998-09-30 | |
PCT/US1999/022520 WO2000018434A1 (en) | 1998-09-30 | 1999-09-30 | Mutant cholera holotoxin as an adjuvant |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1117435T3 true DK1117435T3 (da) | 2008-03-17 |
Family
ID=22289805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK99951639T DK1117435T3 (da) | 1998-09-30 | 1999-09-30 | Muteret cholera-holotoxin som adjuvans |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1117435B1 (pt) |
JP (1) | JP4673974B2 (pt) |
KR (1) | KR100659803B1 (pt) |
CN (1) | CN1197618C (pt) |
AT (1) | ATE378066T1 (pt) |
AU (1) | AU770333B2 (pt) |
BR (1) | BR9914160A (pt) |
CA (1) | CA2344740C (pt) |
CY (1) | CY1107276T1 (pt) |
DE (1) | DE69937571T2 (pt) |
DK (1) | DK1117435T3 (pt) |
ES (1) | ES2293735T3 (pt) |
IL (2) | IL142231A0 (pt) |
MX (1) | MXPA01003228A (pt) |
PT (1) | PT1117435E (pt) |
WO (1) | WO2000018434A1 (pt) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9513371D0 (en) | 1995-06-30 | 1995-09-06 | Biocine Spa | Immunogenic detoxified mutant toxins |
DK0725653T3 (da) | 1993-10-05 | 2004-10-11 | Celltech Pharmaceuticals Ltd | Vaccinepræparater |
GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
GB9622660D0 (en) | 1996-10-31 | 1997-01-08 | Biocine Spa | Immunogenic detoxified mutant toxin |
US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
US7115730B1 (en) | 1999-04-27 | 2006-10-03 | Chiron Srl | Immunogenic detoxified mutant E. coli LT-A-toxin |
WO2002000885A2 (en) | 2000-06-23 | 2002-01-03 | American Cyanamid Company | Assembly of wild-type and chimeric influenza virus-like particles (vlps) |
ATE501161T1 (de) | 2000-12-28 | 2011-03-15 | Wyeth Llc | Rekombinantes schutzprotein aus streptococcus pneumoniae |
EP2261241A1 (en) | 2001-04-16 | 2010-12-15 | Wyeth Holdings Corporation | Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
JP2004535187A (ja) | 2001-06-07 | 2004-11-25 | ワイス・ホールデイングス・コーポレーシヨン | アジュバントとしてのコレラホロトキシンの突然変異形 |
WO2002098369A2 (en) | 2001-06-07 | 2002-12-12 | Wyeth Holdings Corporation | Mutant forms of cholera holotoxin as an adjuvant |
JP4592284B2 (ja) | 2001-07-27 | 2010-12-01 | カイロン ソチエタ ア レスポンサビリタ リミタータ | 髄膜炎菌付着因子 |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
GB0129007D0 (en) * | 2001-12-04 | 2002-01-23 | Chiron Spa | Adjuvanted antigenic meningococcal compositions |
BR0308441A (pt) | 2002-03-15 | 2005-01-18 | Wyeth Corp | Proteìna variante de p4 de haemophilus influenzae não tipificável, composição imunogênica, molécula de nucleotìdeo isolada, célula hospedeira, e, métodos para induzir uma resposta imune em um ser humano contra h. influenzae não tipificável, e para produzir uma proteìna variante de p4 |
US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
US20060251675A1 (en) * | 2003-03-17 | 2006-11-09 | Michael Hagen | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
US20070253964A1 (en) * | 2003-04-16 | 2007-11-01 | Zlotnick Gary W | Novel Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease |
US8071652B2 (en) | 2003-08-21 | 2011-12-06 | The Board Of Regents Of The University Of Texas System | Method of treating irritable bowel syndrome |
TWI357414B (en) | 2003-12-17 | 2012-02-01 | Wyeth Llc | Aβ immunogenic peptide carrier conjugates and meth |
PT1701968E (pt) | 2003-12-17 | 2015-09-11 | Wyeth Llc | Conjugados de transportadores de péptidos imunogénicos e métodos para produzir os mesmos |
GB0410220D0 (en) | 2004-05-07 | 2004-06-09 | Kirkham Lea Ann | Mutant pneumolysin proteins |
CN1953991A (zh) | 2004-05-21 | 2007-04-25 | 惠氏公司 | 变异的金黄色葡萄球菌纤连蛋白结合蛋白 |
TW200613554A (en) | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
KR101346989B1 (ko) | 2004-10-06 | 2014-02-06 | 메디뮨 엘엘씨 | 냉장 온도 안정성 인플루엔자 백신 조성물 |
US8445000B2 (en) | 2004-10-21 | 2013-05-21 | Wyeth Llc | Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens |
US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
ME01334B (me) | 2005-04-08 | 2013-12-20 | Wyeth Llc | Polivalentni pripravak konjugata pneumokoknog polisaharida s proteinom |
TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
KR101495549B1 (ko) | 2006-07-13 | 2015-02-25 | 와이어쓰 엘엘씨 | 당단백질의 생산 |
CA2666317C (en) | 2006-11-03 | 2013-08-06 | Wyeth | Glycolysis-inhibiting substances in cell culture |
AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
JP5586235B2 (ja) | 2007-03-02 | 2014-09-10 | ワイス・エルエルシー | ポリペプチドの産生のための細胞培養における銅およびグルタミン酸塩の使用 |
EP2328928A2 (en) | 2008-08-25 | 2011-06-08 | Dana-Farber Cancer Institute, Inc. | Conserved influenza hemagglutinin epitope and antibodies thereto |
AR074273A1 (es) | 2008-11-05 | 2011-01-05 | Wyeth Corp | Composicion inmunigenica de multiples componentes para la prevencion de la enfermedad estreptococica beta-hemolitica bhs. uso. metodo |
EP2346529B1 (en) | 2008-11-12 | 2016-02-10 | Theraclone Sciences, Inc. | Human m2e peptide immunogens |
CA2799732A1 (en) | 2010-05-19 | 2011-11-24 | Bioproperties Pty Ltd | Methods relating to an attenuated mycoplasma |
KR101609032B1 (ko) | 2010-06-04 | 2016-04-04 | 와이어쓰 엘엘씨 | 스트렙토코커스 뉴모니아 백신 제제 |
RU2580620C2 (ru) | 2010-08-23 | 2016-04-10 | ВАЙЕТ ЭлЭлСи | СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086 |
PE20140173A1 (es) | 2010-09-10 | 2014-02-20 | Wyeth Llc | Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis |
ITMI20111182A1 (it) | 2011-06-28 | 2012-12-29 | Canio Buonavoglia | Vaccino per coronavirus canino |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
MY198910A (en) | 2012-03-09 | 2023-10-02 | Pfizer | Neisseria meningitidis compositions and methods thereof |
KR102057217B1 (ko) | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
CN104854128A (zh) | 2012-07-19 | 2015-08-19 | 硕腾有限责任公司 | 牛流感病毒组合物 |
AU2013295770A1 (en) | 2012-07-27 | 2015-01-29 | Zoetis Services Llc | Tick toxin compositions |
RU2724840C2 (ru) | 2012-08-16 | 2020-06-25 | Пфайзер Инк. | Способы гликоконъюгирования и композиции |
KR20140075201A (ko) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
KR20140075196A (ko) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
EP2964665B1 (en) | 2013-03-08 | 2018-08-01 | Pfizer Inc | Immunogenic fusion polypeptides |
JP2016512841A (ja) | 2013-03-15 | 2016-05-09 | ゾエティス・サービシーズ・エルエルシー | 多価ワクチンによるb.トレハロシ感染に対するウシの干渉効果 |
MX369534B (es) | 2013-09-08 | 2019-11-11 | Pfizer | Composiciones de neisseria meningitidis y sus metodos. |
WO2015110940A2 (en) | 2014-01-21 | 2015-07-30 | Pfizer Inc. | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof |
SI3583947T1 (sl) | 2014-01-21 | 2024-01-31 | Pfizer Inc. | Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati |
ES2930318T3 (es) | 2014-02-14 | 2022-12-09 | Pfizer | Conjugados glucoproteicos inmunogénicos |
CN107249626A (zh) | 2015-02-19 | 2017-10-13 | 辉瑞大药厂 | 脑膜炎奈瑟球菌组合物及其方法 |
MX2018001841A (es) | 2015-08-14 | 2018-08-01 | Zoetis Services Llc | Composiciones de mycoplasma bovis. |
EP3402878A1 (en) | 2016-01-11 | 2018-11-21 | Zoetis Services LLC | Novel cross protective vaccine compositions for porcine epidemic diarrhea virus |
EP3474890A1 (en) | 2016-06-22 | 2019-05-01 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. | Pneumococcal polysaccharide-protein conjugate composition |
EP3269385A1 (en) | 2016-07-12 | 2018-01-17 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Pneumococcal polysaccharide-protein conjugate composition |
SG11201906519RA (en) | 2017-01-31 | 2019-08-27 | Pfizer | Neisseria meningitidis compositions and methods thereof |
GB201703529D0 (en) | 2017-03-06 | 2017-04-19 | Cambridge Entpr Ltd | Vaccine composition |
US10525119B2 (en) | 2017-03-31 | 2020-01-07 | Boston Medical Center Corporation | Methods and compositions using highly conserved pneumococcal surface proteins |
ES2967001T3 (es) | 2017-06-23 | 2024-04-25 | Affinivax Inc | Composiciones inmunogénicas |
EP3574915A1 (en) | 2018-05-29 | 2019-12-04 | Neovacs | Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity |
CA3148824A1 (en) | 2019-07-31 | 2021-02-04 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same |
EP4136219A1 (en) | 2020-04-16 | 2023-02-22 | Par'Immune SAS | 28 kda gst proteins from schistosoma for the treatment of vasculitis |
EP3900739A1 (en) | 2020-04-21 | 2021-10-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein |
EP4213874A1 (en) | 2020-09-17 | 2023-07-26 | Neovacs | Immunogenic product comprising an ige fragment for treating ige-mediated inflammatory disorders |
WO2024069420A2 (en) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Immunogenic compositions comprising an rsv f protein trimer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL101715A (en) * | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
GB9513371D0 (en) * | 1995-06-30 | 1995-09-06 | Biocine Spa | Immunogenic detoxified mutant toxins |
EP0840796A2 (en) * | 1995-07-26 | 1998-05-13 | Maxim Pharmaceuticals | Mucosal delivery of polynucleotides |
GB9603314D0 (en) * | 1996-02-16 | 1996-04-17 | Biocine Spa | Immunogenic detoxified mutant toxins |
WO1998045324A1 (en) * | 1997-04-04 | 1998-10-15 | The Uab Research Foundation | Use of cholera toxin mutants as mucosal adjuvants |
-
1999
- 1999-09-30 JP JP2000571951A patent/JP4673974B2/ja not_active Expired - Fee Related
- 1999-09-30 AT AT99951639T patent/ATE378066T1/de not_active IP Right Cessation
- 1999-09-30 BR BR9914160-4A patent/BR9914160A/pt not_active Application Discontinuation
- 1999-09-30 CN CNB998115576A patent/CN1197618C/zh not_active Expired - Fee Related
- 1999-09-30 IL IL14223199A patent/IL142231A0/xx unknown
- 1999-09-30 DE DE69937571T patent/DE69937571T2/de not_active Expired - Lifetime
- 1999-09-30 AU AU64039/99A patent/AU770333B2/en not_active Ceased
- 1999-09-30 ES ES99951639T patent/ES2293735T3/es not_active Expired - Lifetime
- 1999-09-30 KR KR1020017003968A patent/KR100659803B1/ko not_active IP Right Cessation
- 1999-09-30 PT PT99951639T patent/PT1117435E/pt unknown
- 1999-09-30 DK DK99951639T patent/DK1117435T3/da active
- 1999-09-30 WO PCT/US1999/022520 patent/WO2000018434A1/en active IP Right Grant
- 1999-09-30 EP EP99951639A patent/EP1117435B1/en not_active Expired - Lifetime
- 1999-09-30 CA CA2344740A patent/CA2344740C/en not_active Expired - Fee Related
- 1999-09-30 MX MXPA01003228A patent/MXPA01003228A/es not_active IP Right Cessation
-
2001
- 2001-03-25 IL IL142231A patent/IL142231A/en not_active IP Right Cessation
-
2008
- 2008-02-01 CY CY20081100125T patent/CY1107276T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1117435A1 (en) | 2001-07-25 |
WO2000018434A1 (en) | 2000-04-06 |
EP1117435B1 (en) | 2007-11-14 |
PT1117435E (pt) | 2008-02-21 |
KR100659803B1 (ko) | 2006-12-19 |
DE69937571D1 (de) | 2007-12-27 |
CA2344740A1 (en) | 2000-04-06 |
CA2344740C (en) | 2011-11-22 |
BR9914160A (pt) | 2001-06-26 |
KR20010085859A (ko) | 2001-09-07 |
MXPA01003228A (es) | 2003-06-24 |
DE69937571T2 (de) | 2008-09-04 |
ATE378066T1 (de) | 2007-11-15 |
IL142231A (en) | 2010-05-31 |
CN1320043A (zh) | 2001-10-31 |
IL142231A0 (en) | 2002-03-10 |
CY1107276T1 (el) | 2012-11-21 |
CN1197618C (zh) | 2005-04-20 |
ES2293735T3 (es) | 2008-03-16 |
JP2002525093A (ja) | 2002-08-13 |
AU770333B2 (en) | 2004-02-19 |
AU6403999A (en) | 2000-04-17 |
JP4673974B2 (ja) | 2011-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1117435T3 (da) | Muteret cholera-holotoxin som adjuvans | |
DE60234695D1 (de) | Mutantenformen von cholera holotoxin als adjuvans | |
MXPA03011135A (es) | Formas mutantes de holotoxina de colera como adyuvante. | |
BR9906927A (pt) | Proteìnas de neisseria meningitidis | |
DE60044005D1 (de) | 85 kDa Antigen von Neisseria | |
ATE297190T1 (de) | Mikroemulsionen mit adsorbierten makromolekülen und mikropartikeln | |
DK1800692T3 (da) | Immunologiske sammensætninger og vacciner indeholdende N-formyl-methionyl-peptid som adjuvans | |
WO2004083251A3 (en) | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein | |
NO20054701L (no) | Vaksinesammensetninger som inneholder 3-0-deacetylert monofosforyl lipid A | |
HK1078271A1 (en) | Attenuated gram negative bacteria | |
NO20015074D0 (no) | Nye sammensetninger | |
DE60226175D1 (de) | Mycobakterieller impfstoff | |
GEP20053446B (en) | Adjuvant Combination Formulations | |
WO2000050073A3 (en) | Caulobacter lps immunoadjuvant | |
FI934331A0 (fi) | Nya proteaser | |
DK0757556T3 (da) | Borrelia Burgdorferi-bakterin | |
DK1350796T3 (da) | Attenuerede gramnegative bakterier | |
DE60232413D1 (en) | Ltb4 als adjuvans für impfstoffe | |
DK0721782T3 (da) | Influenzavaccine indeholdende pertussistoksin | |
RU2227043C2 (ru) | Антигены neisseria meningitidis и композиции |